靶向肠黏膜屏障的糖类化合物研究进展  

Research progress in carbohydrate compounds targeting the intestinal barrier

作　　者：陈钱悦 张宇飞 孙一立 蒋昊文 CHEN Qian-yue;ZHANG Yu-fei;SUN Yi-li;JIANG Hao-wen(Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250117;Shandong Laboratory of Yantai Drug Discovery,Bohai Rim Advanced Research Institute for Drug Discovery,Yantai Shandong 264117;Anhui University of Chinese Medicine,Hefei 230012)

机构地区：[1]山东第一医科大学,济南250117 [2]烟台新药创制山东省实验室,中科环渤海(烟台)药物高等研究院,山东烟台264117 [3]安徽中医药大学,合肥230012

出　　处：《中南药学》2025年第3期776-781,共6页Central South Pharmacy

基　　金：山东省自然科学基金青年基金(No.ZR2024QC286)。

摘　　要：肠黏膜屏障作为人体的重要防御系统,是避免细菌、毒素等与内环境接触的关键。肠黏膜屏障的破坏或紊乱会导致炎症性肠病、肠易激综合征和肠漏综合征等疾病的发生发展。糖类在为人体提供能量的同时还在代谢调节和稳态维持方面起到重要作用。糖类药物是由具有生物活性的糖类化合物及其衍生物组成的一类重要药物,具有毒副作用低的优点。本文旨在对改善肠黏膜屏障缺陷的糖类化合物进行综述,以期为后续糖类化合物单独成药或联合用药提供理论基础及新的研究思路。As an important defense system of the human body,the intestinal barrier is the key to avoid the contact of bacteria and toxins with the internal environment.Damage or dysregulation of the intestinal barrier may lead to the development of diseases such as inflammatory bowel disease,irritable bowel syndrome,and leaky gut syndrome.Carbohydrates not only provide energy for the human body,but also play an important role in metabolic regulation and homeostasis maintenance.Carbohydrate-based drugs,consisting of biologically active carbohydrate compounds and their derivatives,are characterized by low toxicity and side effects.This paper reviewed carbohydrate compounds to improve the intestinal barrier deficiencies,and provide a theoretical foundation and new research directions for carbohydrate compounds as standalone drugs or combination therapy.

关 键 词：肠黏膜屏障功能缺陷 糖类化合物 肠道疾病 肠黏膜屏障 

分 类 号：R322[医药卫生—人体解剖和组织胚胎学]